SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 24.660.0%9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Fuzzy1/30/2018 8:15:23 AM
   of 9523
 
Pfizer Inc. ( PFE) reported fourth-quarter and full-year 2017 results before markets opened Tuesday. The pharmaceuticals giant posted quarterly adjusted diluted earnings per share (EPS) of $0.62 and revenues of $13.7 billion. In the same period a year ago, Pfizer reported EPS of $0.42 on revenues of $13.63 billion. Fourth-quarter results also compare to consensus estimates for EPS of $0.56 and $13.68 billion in revenues.

For the full year, Pfizer said it had revenues of $52.55 billion and adjusted EPS of $2.65, compared to revenues of $52.82 billion and $2.40 per share a year ago. Analysts were looking for revenues of $52.53 billion and EPS of $2.60.

The company reported a fourth-quarter and full-year benefit of $10.7 billion related to the new tax law. The benefit includes the negative $15 billion impact of the repatriation tax that the company plans to pay over the next eight years.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext